These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 11801587)

  • 41. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.
    Hamill RJ; Sobel JD; El-Sadr W; Johnson PC; Graybill JR; Javaly K; Barker DE
    Clin Infect Dis; 2010 Jul; 51(2):225-32. PubMed ID: 20536366
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Amphotericin B lipid complex.
    Rapp RP; Gubbins PO; Evans ME
    Ann Pharmacother; 1997 Oct; 31(10):1174-86. PubMed ID: 9337444
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
    Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
    Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
    Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.
    Maertens JA; Madero L; Reilly AF; Lehrnbecher T; Groll AH; Jafri HS; Green M; Nania JJ; Bourque MR; Wise BA; Strohmaier KM; Taylor AF; Kartsonis NA; Chow JW; Arndt CA; DePauw BE; Walsh TJ;
    Pediatr Infect Dis J; 2010 May; 29(5):415-20. PubMed ID: 20431381
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
    Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole.
    Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga MT; Miranda Y; del Valle O; Cossum PA; Wallace TL
    J Antimicrob Chemother; 1999 Sep; 44(3):397-401. PubMed ID: 10511410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management.
    Collazos J; Martínez E; Mayo J; Ibarra S
    Clin Infect Dis; 2001 Oct; 33(7):E75-82. PubMed ID: 11528589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
    Bruynesteyn K; Gant V; McKenzie C; Pagliuca T; Poynton C; Kumar RN; Jansen JP
    Eur J Haematol; 2007 Jun; 78(6):532-9. PubMed ID: 17419744
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
    Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
    J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The lipid formulations of amphotericin B.
    Herbrecht R; Natarajan-Amé S; Nivoix Y; Letscher-Bru V
    Expert Opin Pharmacother; 2003 Aug; 4(8):1277-87. PubMed ID: 12877636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
    Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
    N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies.
    Mehta J; Kelsey S; Chu P; Powles R; Hazel D; Riley U; Evans C; Newland A; Treleaven J; Singhal S
    Bone Marrow Transplant; 1997 Jul; 20(1):39-43. PubMed ID: 9232254
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever.
    Ellis M; Bernsen R; Ali-Zadeh H; Kristensen J; Hedström U; Poughias L; Bresnik M; Al-Essa A; A Stevens D
    J Med Microbiol; 2009 Nov; 58(Pt 11):1474-1485. PubMed ID: 19589901
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.
    Ramaswamy M; Peteherych KD; Kennedy AL; Wasan KM
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1184-91. PubMed ID: 11257033
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.
    Hooshmand-Rad R; Reed MD; Chu A; Gotz V; Morris JA; Weinberg J; Dominguez EA
    Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Voriconazole versus amphotericin B in cancer patients with neutropenia.
    Jørgensen KJ; Gøtzsche PC; Johansen HK
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004707. PubMed ID: 16437492
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reversible dilated cardiomyopathy related to amphotericin B therapy.
    Danaher PJ; Cao MK; Anstead GM; Dolan MJ; DeWitt CC
    J Antimicrob Chemother; 2004 Jan; 53(1):115-7. PubMed ID: 14657095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-dose amphotericin B lipid complex for the treatment of persistent fever of unknown origin in patients with hematologic malignancies and prolonged neutropenia.
    Martino R; Subirá M; Domingo-Albós A; Sureda A; Brunet S; Sierra J
    Chemotherapy; 1999; 45(3):205-12. PubMed ID: 10224343
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.